BioPharmSignal logoBioPharmSignal

Biotech News

MediciNova to Participate in the Maxim Growth Summit

MediciNova (MNOV)MediciNovaCompany update

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that management will participate in the Maxim Growth

Related news

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

MNOVMediciNova2026-09-24 10:00 EST

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

SUPNSupernus2026-09-02 20:30 EST

Supernus Pharmaceuticals to Participate in September Investor Conferences

ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

ANNXAnnexon, Inc.2026-09-02 12:00 EST

Annexon to Participate in Upcoming September Investor Conferences

TNXPTonix Pharmaceuticals2026-09-02 11:00 EST

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

AXSMAxsome2026-09-02 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

HRMYHarmony Biosciences2026-08-27 12:05 EST

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

View all latest news

MediciNova

MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.

Recent company news

MNOVMediciNova2026-10-06 10:00 EST

MediciNova to Participate in the Maxim Growth Summit

MNOVMediciNova2026-09-28 10:00 EST

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-09-24 10:00 EST

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

Stock data

Close
1.65 USD
Market cap
65.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States